Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up.

Published on Dec 1, 2014in British Journal of Haematology5.518
· DOI :10.1111/BJH.13055
Ama Z.S. Rohatiner42
Estimated H-index: 42
(St Bartholomew's Hospital),
Matthew L. Smith12
Estimated H-index: 12
(St Bartholomew's Hospital)
+ 14 AuthorsAndrew Lister22
Estimated H-index: 22
(St Bartholomew's Hospital)
📖 Papers frequently viewed together
1 Citations
1 Citations
#1Anjali Shah (University of Oxford)H-Index: 13
#2Therese M.-L. Andersson (KI: Karolinska Institutet)H-Index: 35
Last. Paul C. Lambert (KI: Karolinska Institutet)H-Index: 62
view all 5 authors...
The 5-year relative survival of adults diagnosed with acute myeloid leukaemia (AML) was less than 10% during the 1970s and 1980s in England. This population-based study estimated the 5-year relative survival and ‘cure’ for 48 380 adult patients diagnosed with AML in England during 1971–2006. Relative survival and cure mixture models were used to produce estimates of 5-year relative survival and the percentage ‘cured’. ‘Cure’ was defined as the proportion of a group of survivors for whom there is...
112 CitationsSource
#1Edo Vellenga (UMCG: University Medical Center Groningen)H-Index: 89
#2Wim H. van der Putten (Erasmus University Medical Center)H-Index: 84
Last. Bob Löwenberg (Erasmus University Medical Center)H-Index: 121
view all 17 authors...
We report the results of a prospective, randomized phase 3 trial evaluating autologous peripheral blood stem cell transplantation (ASCT) versus intensive consolidation chemotherapy in newly diagnosed AML patients in complete remission (CR1). Patients with AML (16-60 years) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high-dose cyclophosphamide and busulfan. Of patien...
91 CitationsSource
#1Hugo F. Fernandez (USF: University of South Florida)H-Index: 33
#1Hugo F. Fernandez (USF: University of South Florida)H-Index: 17
Last. Martin S. Tallman (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 94
view all 11 authors...
We report the results of a prospective, randomized phase 3 trial evaluating the use of gemtuzumab ozogamicin (GO) in an intensive consolidation approach in 657 patients 17-60 years of age. Patients in first complete remission (CR1) after cytarabine and standard- or high-dose daunorubicin induction received 2 cycles of consolidation with high-dose cytarabine followed by peripheral blood progenitor cell collection. The 352 patients who entered consolidation were randomized to receive GO (n = 132) ...
52 CitationsSource
#1Åsa Rangert Derolf (Karolinska University Hospital)H-Index: 18
#2Sigurdur Y. Kristinsson (Karolinska University Hospital)H-Index: 48
Last. Magnus Björkholm (Karolinska University Hospital)H-Index: 79
view all 6 authors...
We evaluated survival patterns for all registered acute myeloid leukemia (AML) patients diagnosed in Sweden in 1973 to 2005 (N = 9729; median age, 69 years). Patients were categorized into 6 age groups and 4 calendar periods (1973-1980, 1981-1988, 1989-1996, and 1997-2005). Relative survival ratios were computed as measures of patient survival. One-year survival improved over time in all age groups, whereas 5- and 10-year survival improved in all age groups, except for patients 80+ years. The 5-...
117 CitationsSource
#2Holly GundackerH-Index: 13
Last. Stephen H. PetersdorfH-Index: 36
view all 8 authors...
We conducted a retrospective analysis of 968 adults with acute myeloid leukemia (AML) on 5 recent Southwest Oncology Group trials to understand how the nature of AML changes with age. Older study patients with AML presented with poorer performance status, lower white blood cell counts, and a lower percentage of marrow blasts. Multidrug resistance was found in 33% of AMLs in patients younger than age 56 compared with 57% in patients older than 75. The percentage of patients with favorable cytogen...
954 CitationsSource
#1Sherif S. Farag (OSU: Ohio State University)H-Index: 20
#2Amy S. Ruppert (OSU: Ohio State University)H-Index: 45
Last. Clara D. Bloomfield (OSU: Ohio State University)H-Index: 142
view all 18 authors...
Purpose Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML). Patients and Methods In 490 patients, induction included cytarabine and daunorubicin (AD) or cytarabine and escalated doses of daunorubicin and etoposide ± PSC-833 (ADE/ADEP). Intensification included one cycle of high-dose cytarabine (HDAC) followed by etoposide/cyclophosphamide and mitoxantrone/diaziquone (group I), three HDAC cycles (group ...
115 CitationsSource
During the last three decades it has become apparent that the majority of cases of acute myeloid leukaemia (AML) are characterized by at least one of a variety of recurrent chromosomal abnormalities. These changes have been found in many instances to correlate closely with distinct morphological features and clinical characteristics, the molecular basis of which is becoming increasingly understood. Furthermore, diagnostic karyotype has been shown to be a key determinant of outcome in AML, with m...
139 CitationsSource
#1A. Z. S. RohatinerH-Index: 31
#2R. BassanH-Index: 1
Last. T. A. ListerH-Index: 64
view all 11 authors...
Background: Debate and controversy remain as to the optimal post-remission therapy for younger patients with acute myelogenous leukaemia (AML). The aim of this study was to evaluate high-dose treatment (HDT) with autologous bone marrow support (ABMS) as consolidation of first complete remission (CR). Patients and methods: One hundred forty-four patients (AML-M3 excluded, median age 38 years, range 15-49 years) received remission induction therapy comprising: adriamycin 25 mg/m 2 , days 1-3, cyto...
12 CitationsSource
#1Alan Kenneth Burnett (University of Wales)H-Index: 94
#2Anthony H. Goldstone (UCLH: University College Hospital)H-Index: 82
Last. Keith WheatleyH-Index: 77
view all 7 authors...
Background Three strategies are used to prevent relapse in patients with acute myeloid leukaemia in first remission. Most of those with suitable donors are offered allogeneic haemopoietic-stem-cell transplant. Other patients may receive intensive chemotherapy or autologous transplantation; we undertook this randomised prospective trial to assess which is the better option. Methods After three courses of intensive chemotherapy, bone marrow was harvested from patients (<56 years of age) in remissi...
522 CitationsSource
#1Jean-Luc HarousseauH-Index: 108
#2Jean-Yves CahnH-Index: 63
Last. Patrick HervéH-Index: 43
view all 20 authors...
Three intensive consolidation strategies are currently proposed to younger adults with acute myeloid leukemia (AML) in first complete remission (CR): allogeneic or autologous bone marrow transplantation (BMT) and intensive consolidation chemotherapy (ICC). Patients aged 15 to 50 years with de novo AML received an induction treatment with 7 days of cytarabine and either idarubicin or rubidazone. After achievement of a CR, patients up to the age of 40 and having an HLA-identical sibling were assig...
320 CitationsSource
Cited By4
#1Diego Adrianzen Herrera (Albert Einstein College of Medicine)H-Index: 8
#2Noah Kornblum (Albert Einstein College of Medicine)H-Index: 8
Last. Ioannis Mantzaris (Albert Einstein College of Medicine)H-Index: 14
view all 10 authors...
Abstract Introduction In the United States, autologous hematopoietic cell transplantation (autoHCT) has fallen out of favor over chemotherapy consolidation for non–high-risk acute myeloid leukemia (AML) when allogeneic hematopoietic cell transplantation (alloHCT) is unfeasible, which is common in racial minorities because of donor registry under-representation and socioeconomic challenges. We compared autoHCT consolidation outcomes with chemotherapy alone in a minority-rich cohort in the Bronx. ...
#1Olla Al-Jaibaji (Centre for Life)H-Index: 2
#2Stephen Swioklo (Centre for Life)H-Index: 5
Last. Che J. Connon (Centre for Life)H-Index: 32
view all 3 authors...
AbstractIntroduction: Cornea is a transparent, robust tissue that comprises highly organized cells. Disruption of this specialized tissue, can lead to scarring and subsequent blindness, making corneal damage a considerable challenge worldwide. At present, the available medical treatments are unable to address the wide range of corneal diseases. Mesenchymal stem cells (MSCs) have increasingly been investigated for their regenerative effect on ocular surface injury due to their unique ability for ...
3 CitationsSource
#1Renato BassanH-Index: 27
#2Tamara IntermesoliH-Index: 21
Last. Alessandro Rambaldi (University of Milan)H-Index: 114
view all 30 authors...
Here we evaluated whether sequential high-dose chemotherapy (sHD) increased the early complete remission (CR) rate in acute myelogenous leukemia (AML) compared with standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy. This study enrolled 574 patients (age, 16-73 years; median, 52 years) who were randomly assigned to ICE (n = 286 evaluable) or sHD (2 weekly 3-day blocks with cytarabine 2 g/m 2 twice a day for 2 days plus idarubicin; n = 286 evaluable). Responsive patients were r...
10 CitationsSource
#1Tsila ZuckermanH-Index: 22
#2Ofrat Beyar-KatzH-Index: 6
Last. Jacob M. RoweH-Index: 85
view all 3 authors...
Despite numerous studies, the best postremission therapy in acute myeloid leukemia (AML) is a subject of intense controversy. Major prognostic factors for disease outcome are the genetic alterations of AML, patient's age, and performance status. AML is more common in older adults, with a median age of 72 years. However, in this age group the unfavorable cytogenetics dominates at a time when biologically it may be most difficult to administer optimal intensive therapy.Autologous stem cell transpl...
8 CitationsSource